At least eight of the major pharma companies have deals with another pharma to combine two investigational or recently approved agents in clinical trials for cancer. Additionally, companies have internal programs combining two investigational or recently approved agents, a selection of which are shown. (A) Licensed from Plexxikon Inc. which was acquired by Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568) in April; (B) Licensed from Exelixis Inc. (NASDAQ:EXEL); (C) AstraZeneca plc (LSE:AZN; NYSE:AZN) has rights to selumetinib for oncology indications from Array BioPharma Inc. (NASDAQ:ARRY); Sources: BCIQ: BioCentury Online Intelligence; www.clinicaltrials.gov; company websites